The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.

Richardson KM, Schembre SM, Jospe MR, Widmer A, Silver HJ

Diabetes, obesity & metabolism21 Apr 2025Cited by 6 (Europe PMC)

PMID40259488PMCIDPMC12146451DOI10.1111/dom.16395PepBankPUB-40259488

Read at source PubMedAsk about this study

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study9

1 result from studies that gave the peptide. 1 result from people.

01HumanRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, liraglutide had smaller baseline-adjusted improvement in the added-sugar HEI component than caloric restriction (P=0.002); no difference coefficient was reported.
In plain wordsIn obesity and prediabetes, liraglutide improved the added-sugar diet-quality score less than dietitian-supported caloric restriction after baseline adjustment.
Peptide
Liraglutide
Outcome
DecreaseBaseline-adjusted added-sugar HEI-component improvement
Study
n: not reported in source
Comparator
Dietitian-supported caloric restriction
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Studied dose
1.8 mg/day · 14 weeksAs given in this study (human).
Measurements
P-value
0.002
baseline-adjusted caloric-restriction versus liraglutide added-sugar HEI component
Source sentences
Summary
However, the caloric restriction group significantly improved their HEI component score for added sugar compared to the liraglutide group (p = 0.002) when adjusted for baseline intake.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
Report a problemFND-4025948806

Studies that did not test the peptide alone8

In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Liraglutide.

02HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, protein calorie-percentage changes differed across liraglutide/caloric-restriction/DPP-4-inhibitor groups (P=0.037); caloric restriction had the greatest reported change, with no liraglutide-specific coefficient.
In plain wordsIn obesity and prediabetes, protein calorie-percentage changes differed across liraglutide, diet and DPP-4-inhibitor groups; liraglutide’s individual effect was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedProtein calorie-percentage change across treatment groups
Study
n = 70
Comparator
Liraglutide, caloric restriction and DPP-4-inhibitor groups; omnibus comparison
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Omnibus P-value
0.037
between-group calorie-percentage change, not a liraglutide-specific pairwise test
Source sentences
Summary
Significant differences in change in percent calories from protein (p = 0.037), carbohydrates (p = 0.019) and added sugar (p = 0.002) were observed across groups, with those in the caloric restriction group having the greatest increase in protein and decreases in carbohydrates and added sugar.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948801
03HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, carbohydrate calorie-percentage changes differed across liraglutide/caloric-restriction/DPP-4-inhibitor groups (P=0.019); caloric restriction had the greatest reported change, with no liraglutide-specific coefficient.
In plain wordsIn obesity and prediabetes, carbohydrate calorie-percentage changes differed across liraglutide, diet and DPP-4-inhibitor groups; liraglutide’s individual effect was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedCarbohydrate calorie-percentage change across treatment groups
Study
n = 70
Comparator
Liraglutide, caloric restriction and DPP-4-inhibitor groups; omnibus comparison
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Omnibus P-value
0.019
between-group calorie-percentage change, not a liraglutide-specific pairwise test
Source sentences
Summary
Significant differences in change in percent calories from protein (p = 0.037), carbohydrates (p = 0.019) and added sugar (p = 0.002) were observed across groups, with those in the caloric restriction group having the greatest increase in protein and decreases in carbohydrates and added sugar.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948802
04HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, added-sugar calorie-percentage changes differed across liraglutide/caloric-restriction/DPP-4-inhibitor groups (P=0.002); caloric restriction had the greatest reported change, with no liraglutide-specific coefficient.
In plain wordsIn obesity and prediabetes, added-sugar calorie-percentage changes differed across liraglutide, diet and DPP-4-inhibitor groups; liraglutide’s individual effect was unstated.
Peptide
Liraglutide
Outcome
Direction not reportedAdded-sugar calorie-percentage change across treatment groups
Study
n = 70
Comparator
Liraglutide, caloric restriction and DPP-4-inhibitor groups; omnibus comparison
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Measurements
Omnibus P-value
0.002
between-group calorie-percentage change, not a liraglutide-specific pairwise test
Source sentences
Summary
Significant differences in change in percent calories from protein (p = 0.037), carbohydrates (p = 0.019) and added sugar (p = 0.002) were observed across groups, with those in the caloric restriction group having the greatest increase in protein and decreases in carbohydrates and added sugar.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948803
05HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, micronutrient intake did not significantly differ across liraglutide/caloric-restriction/DPP-4-inhibitor groups; no individual native-drug contrast was reported.
In plain wordsIn obesity and prediabetes, micronutrient intake showed no significant differences across liraglutide, diet and DPP-4-inhibitor groups.
Peptide
Liraglutide
Outcome
No significant changeMicronutrient intake across groups
Study
n = 70
Comparator
Liraglutide, caloric restriction and DPP-4-inhibitor groups
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Micronutrient intake did not significantly differ between groups nor did Total Healthy Eating Index (HEI)-2020 scores.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948804
06HumanNot a test of Liraglutide aloneRandomized controlled trialEfficacy outcome
In participants with obesity and prediabetes, total healthy eating index-2020 score did not significantly differ across liraglutide/caloric-restriction/DPP-4-inhibitor groups; no individual native-drug contrast was reported.
In plain wordsIn obesity and prediabetes, overall diet-quality scores showed no significant differences across liraglutide, diet and DPP-4-inhibitor groups.
Peptide
Liraglutide
Outcome
No significant changeTotal Healthy Eating Index-2020 score across groups
Study
n = 70
Comparator
Liraglutide, caloric restriction and DPP-4-inhibitor groups
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Micronutrient intake did not significantly differ between groups nor did Total Healthy Eating Index (HEI)-2020 scores.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948805
07HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In participants with obesity and prediabetes, fruit intake recommendations were not met across treatment groups including liraglutide; no native-drug responder proportion or causal effect was reported.
In plain wordsIn obesity and prediabetes, participants across groups including liraglutide did not meet fruit intake recommendations.
Peptide
Liraglutide
Outcome
Not applicableFruit intake recommendation not met across groups
Study
n = 70
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Despite the treatment group, participants failed to meet several of the same nutrition recommendations, including those for fruit, vegetable and dairy intake.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948807
08HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In participants with obesity and prediabetes, vegetable intake recommendations were not met across treatment groups including liraglutide; no native-drug responder proportion or causal effect was reported.
In plain wordsIn obesity and prediabetes, participants across groups including liraglutide did not meet vegetable intake recommendations.
Peptide
Liraglutide
Outcome
Not applicableVegetable intake recommendation not met across groups
Study
n = 70
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Despite the treatment group, participants failed to meet several of the same nutrition recommendations, including those for fruit, vegetable and dairy intake.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948808
09HumanNot a test of Liraglutide aloneRandomized controlled trialOther
In participants with obesity and prediabetes, dairy intake recommendations were not met across treatment groups including liraglutide; no native-drug responder proportion or causal effect was reported.
In plain wordsIn obesity and prediabetes, participants across groups including liraglutide did not meet dairy intake recommendations.
Peptide
Liraglutide
Outcome
Not applicableDairy intake recommendation not met across groups
Study
n = 70
Analysis
Secondary
Outcome group
Appetite and food intake · Metabolic and weight
Source sentences
Summary
Despite the treatment group, participants failed to meet several of the same nutrition recommendations, including those for fruit, vegetable and dairy intake.
3 context sentences(design, population, supporting numbers)
Summary · context
Participants with obesity and prediabetes were randomly assigned 2:1:1 to liraglutide (1.8 mg/day), dietitian-supported caloric restriction (-390 kcals/day) or dipeptidyl peptidase-4 inhibitor (100 mg/day) for 14 weeks.
Summary · context
Dietary intake was assessed via a single 24-h dietary recall pre- and postintervention.
Title · context
The influence of the glucagon-like peptide-1 receptor agonist, liraglutide, on dietary patterns and nutrient intakes in patients with obesity and prediabetes: A secondary analysis of a randomized controlled trial.
In this study, Liraglutide was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Liraglutide.
Report a problemFND-4025948809

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
12 Oct 2026, 11:11 UTC
Study results updated
Version 1
9 Oct 2026, 03:04 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.